| Identification | Back Directory | [Name]
2-((S)-1-((2S,5R)-5-(4-CHLORO-5-FLUORO-2-(TRIFLUOROMETHYL)PHENYL)TETRAHYDROFURAN-2-YL)ETHYL)-7-(4-METHYL-1H-IMIDAZOL-1-YL)-3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONE | [CAS]
1587727-31-8 | [Synonyms]
PF6648671
PF-6648671
PF 6648671
PF-06648671
2-((S)-1-((2S,5R)-5-(4-CHLORO-5-FLUORO-2-(TRIFLUOROMETHYL)PHENYL)TETRAHYDROFURAN-2-YL)ETHYL)-7-(4-METHYL-1H-IMIDAZOL-1-YL)-3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONE
2H-Pyrido[1,2-a]pyrazine-1,6-dione, 2-[(1S)-1-[(2S,5R)-5-[4-chloro-5-fluoro-2-(trifluoromethyl)phenyl]tetrahydro-2-furanyl]ethyl]-3,4-dihydro-7-(4-methyl-1H-imidazol-1-yl)- | [Molecular Formula]
C25H23ClF4N4O3 | [MDL Number]
MFCD31560371 | [MOL File]
1587727-31-8.mol | [Molecular Weight]
538.92 |
| Hazard Information | Back Directory | [Biological Activity]
PF-06648671 is a novel, brain‐penetrable, and orally active γ‐secretase modulator (GSM). PF-06648671 reduces Aβ42 and Aβ40, with concomitant increases in Aβ37 and Aβ38 in vitro. PF-06648671 is used for the study of Alzheimer’s disease[1].
In a cell‐based assay, PF‐06648671 reduces Aβ42 and Aβ40 , with concomitant increases in Aβ37 and Aβ38, without inhibiting the cleavage of Notch or other substrates[1].
PF‐06648671 demonstrates reduces Aβ42 within the brain and CSF following acute oral administration in animals[1]. | [storage]
Store at -20°C | [References]
[1]. Jae Eun Ahn, et al. Pharmacokinetic and Pharmacodynamic Effects of a γ-Secretase Modulator, PF-06648671, on CSF Amyloid-β Peptides in Randomized Phase I Studies. Clin Pharmacol Ther 2020 Jan;107(1):211-220. |
|
| Company Name: |
guoyungurui
|
| Tel: |
18162595016; 18162595016 |
| Website: |
http://www.is0513.com/supplier/25521782/ |
|